June 29, 2015 11:33 AM | 1 min read |
Shares of
Aratana Therapeutics Inc
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NASDAQ: PETX) were surging higher by more than 17 percent Monday after the company announced positive results from its pivotal field effectiveness study of capromorelin (AT-002), the company's innovative therapeutic for appetite stimulation in dogs.Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals.The company noted that in the effectiveness study, dogs were given a 3 mg/kg daily oral dose of capromorelin for four days. These dogs demonstrated a statistically significant increase in appetite compared to a placebo.The study was a randomized, masked, placebo controlled multi-site study with over 200 inappetent dogs. Appetite was assessed with an owner questionnaire after four days of treatment."The results from the pivotal field study demonstrate that capromorelin clearly stimulated appetite in client-owned dogs," Ernst Heinen, DVPM, Ph.D. and Chief Development Officer for Aratana said in a
press release. "We believe it could be a first-in-class approved drug for treating inappetence in dogs."The press release noted that the positive data adds to the "robust" safety and efficacy data that has already been generated in prior studios. In addition, the recent data serves as the final piece of the Effectiveness Technical Section that the company intends to submit to the Food and Drug Administration's Center for Veterinary Medicines as the company pursues marketing approval for capromorelin.Aratana expects to commence commercialization of capromorelin for treatment of inappetence in dogs next year.Shares of Aratana traded recently at $15.80, up 17.5 percent.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.